|
AGL expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.33066907387547E-16 |
| Normal-vs-Stage2 |
2.21289999999819E-05 |
| Normal-vs-Stage3 |
9.54791801177635E-15 |
| Normal-vs-Stage4 |
1.62447832963153E-12 |
| Stage1-vs-Stage2 |
2.644100E-02 |
| Stage1-vs-Stage3 |
7.982100E-02 |
| Stage1-vs-Stage4 |
9.553200E-04 |
| Stage2-vs-Stage3 |
3.223100E-03 |
| Stage2-vs-Stage4 |
1.029540E-04 |
| Stage3-vs-Stage4 |
1.703630E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
2.02279999972355E-07 |
| Normal-vs-Asian |
7.72026886863841E-12 |
| Caucasian-vs-AfricanAmerican |
6.217000E-01 |
| Caucasian-vs-Asian |
8.120000E-01 |
| AfricanAmerican-vs-Asian |
5.289600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.89848137210902E-14 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
6.927400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62969637784727E-12 |
| Normal-vs-Age(41-60Yrs) |
1.66533453693773E-15 |
| Normal-vs-Age(61-80Yrs) |
3.82738285509276E-12 |
| Normal-vs-Age(81-100Yrs) |
6.500600E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.808600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.634000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.657800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.925400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.933400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.388400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.357400E-04 |
| Classical-VS-Follicular |
4.68320000002187E-06 |
| Classical-VS-Other |
7.488000E-01 |
| Classical-VS-Normal |
1.6242562850266E-12 |
| Tall-VS-Follicular |
3.54399953828022E-10 |
| Tall-VS-Other |
1.877220E-01 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
8.945600E-02 |
| Follicular-VS-Normal |
1.213460E-04 |
| Other-VS-Normal |
2.224400E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.84192677671535E-12 |
| Normal-vs-N1 |
1.62447832963153E-12 |
| N0-vs-N1 |
1.176200E-04 |
|
|
